AB-2122: Medi-Cal: Blood lead screening tests.

Session: 2017-2018
Author: Reyes
Status: Vetoed
AAP-CA Position: Support
To view the status of this bill on the State Website, click here.

Would require the Department of Health Care Services to ensure that a child enrolled in Medi-Cal receives blood lead screening tests at 12 and 24 months of age, and that a child 2 to 6 years of age, inclusive, receives a blood lead screening test if there is no record of a previous test for that child. The bill would require the department to report its progress toward blood lead screening tests for all enrolled children, as specified, annually on its Internet Web site, establish a case management monitoring system, and require health care providers to test enrolled children, as specified.

Veto Message:

To the Members of the California State Assembly:

I am returning Assembly Bill 2122 without my signature.

Lead exposure in children is a serious health concern and I share the author’s desire to increase the number of Medi-Cal children who are screened. The department, however, already requires in its contracts with managed care plans and providers that children receive screenings in accordance with federal and state regulations. Updated and more thorough data on periodic screening tests is being developed with the Department of Public Health to assist in tracking compliance.

I believe the department should continue its current efforts working with managed care plans, health care providers and public health officials to determine what additional policies and practices may be necessary to improve screening rates.

Sincerely,

Edmund G. Brown Jr.

AAP Positional Letter



March 26, 2018

The Honorable Jim Wood
Chair, Assembly Health Committee
State Capitol, Room 6005
Sacramento, CA 95814

RE: ​​A​B 2122 (Reyes) Medi-Cal: Blood lead screening tests
AAP-CA Position: Support

Dear Chair Wood,

The American Academy of Pediatrics, California (AAP-CA), representing over 5,000 California pediatricians statewide, strongly supports AB 2122 (Reyes), which would require the Department of Health Care Services to ensure that a child enrolled in Medi-Cal receives blood lead screening tests at 12 and 24 months of age, and that a child 2 to 6 years of age, inclusive, receives a blood lead screening test if there is no record of a previous test for that child. The bill also requires the department to notify parents and health providers when a Medi-Cal enrolled child misses a required blood lead test.

Toxic lead exposure disproportionately impacts low income communities, and, for many children, will lead to permanent and life-long disabilities if not caught early and treated. African-American children and children living in poverty continue to have higher blood lead concentrations.

Lead exposure has been shown to decrease IQ and to cause behavior difficulties (e.g., inattentive, hyperactive, disorganized). Follow-up studies of children with high lead levels has indicated higher rates of failure to graduate from high school, reading disabilities, and greater absenteeism in the final year of high school.1

According to the California Department of Public Health, 88% of lead-poisoned children are enrolled in Medi-Cal. When Medi-Cal children are lead-tested and those exposed to lead are identified, parents and providers can act to minimize the neurotoxin’s developmental harms. According to available data, most Medi-Cal children required to receive these two screenings are not tested. As a result, they are at risk of serious developmental problems from toxic lead.

Pediatrician members of AAP California Chapters 1, 2, 3 and 4 across the state urge you to vote AYE on AB 2122 (Reyes). Thank you for your public service and leadership on behalf of the health and wellbeing of children, youth, and families in California.

Sincerely,

Melissa J. Ruiz, M.D., M.P.H., Fellow of the American Academy of Pediatrics
Early Career Physician Representative, American Academy of Pediatrics, California

cc: Assembly Health Committee Members
Office of Honorable Eloise Reyes, California State Assembly (Author)
AAP-CA Lobbyist Lydia Bourne; Amanda Schafenacker, MD, Senior Policy Analyst